Primary Immune Deficiency Archives - MPR

Primary Immune Deficiency

Gammaplex 10% Gets FDA Approval

Bio Products Laboratory announced that the Food and Drug Administration (FDA) has approved Gammaplex 10% (immune globulin intravenous [human], 10% liquid) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenic purpura (ITP) in adults.

Cuvitru Approved for Primary Immunodeficiency

Shire announced that the Food and Drug Administration (FDA) has approved Cuvitru (immune globulin subcutaneous [human]) 20% solution for the treatment of primary immunodeficiency in patients aged ≥2 years.

HIZENTRA (immune globulin [human]) 20% liquid by CSL Behring

Flexible Dosing Option for Hizentra Approved

CSL Behring announced that the Food and Drug Administration (FDA) has approved a new dosing option for Hizentra (immune serum globulin [human]) 0.2mg/mL (20%) Liquid to include treatment at regular intervals from daily to biweekly in patients with primary immunodeficiency.